Latest Intelligence on Pharmaceuticals and Healthcare in Switzerland

Published within

« | ... | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | » »|

Type Product title / description Pub Price
Expert View
Expert View

Novartis's novel bronchodilator paves way for potent COPD combinations

Novartis has unveiled promising Phase II data for its once-daily bronchodilator, indacaterol (QAB-149). With a long duration of action, rapid onset of action and clean side effects profile, the drug could provide a new standard for bronchodilator therapy in patients with asthma and chronic obstructive pulmonary disease (COPD).

Published By Datamonitor
09 Jun 2005
CommentWire
CommentWire

Roche: buying up for biotech boost

Roche has announced that it will acquire GlycArt for approximately E150 million, in a move that will boost the healthcare giant's position in the biologics, and particularly oncology, markets. The deal promises to strengthen Roche's drug development capabilities and help maintain the large increases in sales drawn from its therapeutic anti-cancer antibodies.

Published By Datamonitor
20 Jul 2005
Expert View
Expert View

Roche reinforces its HIV portfolio

Recently presented data has highlighted the efficacy of Roche and Trimeris' Fuzeon plus new antiretrovirals in treatment-experienced HIV patients. The data forms part of an ongoing program of studies into the use of Fuzeon with several pipeline drugs, including the novel CCR5 inhibitors, and underlines Roche's continued commitment to the HIV market. Datamonitor's Laura Harris reports...

Published By Datamonitor
02 Aug 2005
CommentWire
CommentWire

Novartis: premium price for Chiron still to come

Chiron has snubbed Novartis' offer to acquire the remaining shares of the company that it does not already own, calling the offer "inadequate". Chiron no doubt wants to hold out for a better offer, which is a wise move since, as Novartis will be the key benefactor from the takeover, the Swiss company is likely to significantly increase its bid.

Published By Datamonitor
07 Sep 2005
CommentWire
CommentWire

Avalon/Novartis: publicity before the public

Avalon Pharmaceuticals and Novartis have entered into a collaboration to discover small molecule therapeutic compounds using Avalon's AvalonRx drug discovery engine. AvalonRx has been key to past collaborative agreements with large biotech and pharma companies such as MedImmune and Sanofi-Aventis, but with Avalon's imminent public offering of stock, the Novartis deal could be more significant.

Published By Datamonitor
14 Sep 2005
CommentWire
CommentWire

Novartis/Chiron: a promising cash injection

Novartis has finally satisfied Chiron's board after raising its takeover bid for the firm. This is good, if unsurprising, news for Novartis, as Chiron offers the Swiss drug maker growth opportunities in vaccines and biopharmaceuticals. Indeed, despite its recent woes, Chiron should be a good buy, enabling Novartis to become a key player in the increasingly important vaccine market.

Published By Datamonitor
02 Nov 2005
CommentWire
CommentWire

Novartis/Alnylam: racing against time in flu

Novartis and Alnylam have joined to advance pandemic flu therapeutics based on RNAi through initial clinical testing and eventually regulatory approval. This focus on RNAi R&D is driven by fears that current flu vaccines and antivirals might not be sufficient to protect against the H5N1 pandemic strain and only time will tell whether an approval is granted before the impending pandemic strikes.

Published By Datamonitor
21 Feb 2006
CommentWire
CommentWire

Speedel/Novartis: Rasilez and the renin revolution

Novartis stands on the brink of launching the first innovative treatment for hypertension in over a decade, in the form of Rasilez (aliskiren), thanks to the efforts of the drug's development partner, Speedel. This vindicates the risk Speedel took back in 1998 when it set out to build a business based on big pharma cast-offs, something many believed was doomed to fail.

Published By Datamonitor
10 Mar 2006
CommentWire
CommentWire

Novartis: higher bid to secure Chiron deal

Novartis has increased its offer to acquire Chiron, one the world's leading vaccine producers, in an effort to hasten completion of the deal. The new $5.3 billion bid is expected to appease Chiron shareholders and thereby bring Novartis a step closer to strengthening its position in the global biopharmaceuticals and biogenerics markets.

Published By Datamonitor
05 Apr 2006
CommentWire
CommentWire

Serono: buying not selling

After failing to receive suitably attractive offers, Serono's controlling shareholder has ended discussions concerning a sale of the company, opting instead to focus on growth via acquisitions. Although this shift in strategy has startled investors, it could prove a good move in the long term, if it can sufficiently strengthen Serono's relatively weak pipeline.

Published By Datamonitor
11 Apr 2006

« | ... | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | » »|

No help is available.